Interleukin-12 Gene Transfection Of Dendritic Cells And Ovarian Cancer Cell Fusion As A Preliminary Study Of Ovarian Carcinoma Tumor Vaccine

Ovarian carcinoma remains the most lethal of gynecologic malignancies. Cytoreductive surgery followed by combination chemotherapy is the standard treatment of patients with ovarian cancinoma. However, the overall 5-year survival has been changed little. A new and more effective approach for the treatment is urgently to improve the prognosis. Immune therapy shows a promising trend. T cell immune response plays an important role in tumor immune response, which requires effective antigen presentation. Dendritic cells (DC) are the most potent antigen presenting cells known up to date. Highly-expressing MHC I, II and costimulatory molecules. DC plays a core role in tumor antigen presentation. Interleukin 12 (IL-12) is a heterodimeric cytokine that is produced primarily by antigen-presenting cells, plays a critical role in the induction of cell-mediated immunity and has obvious anti-tumor activity. Therefore, in this study, IL-12 fusion gene is transfected into DC, and is fused to human autologous ovarian carcinoma cells. In this time, the vaccine will not only present antigens, but also express tumor antigen and have the anti-tumor activity.Objection To investigated the immune response of the fusions of autologous ovarian carcinoma cells to DC transfeced with IL-12 gene. Methods rhGM-CSF and rhTNFa were used to generate DC in vitro from cord blood.